LeVasseur Named to United Soccer Coaches Goalkeepers to Watch List Eastern Kentucky University Athletics

Ban policy incoming for Kahnawake Mohawk Council Facebook page Penticton Herald

Facebook groups and a rumour of an open border drive the Ceuta crossing Brussels Signal

A Ventura County man was arrested for allegedly attacking his elderly stepfather with a butcher knife. The Ventura County Sheriff’s Office identified the suspect as Chad Nelson, 40, of Oak Park. On July 30, deputies were called to an assault at a home on the 5900 block of East Sunny Vista Avenue in Oak Park [...]

An updated edition of the June 11, 2026, article.The global automotive industry is in the midst of transformation. Electrification and autonomous driving are reshaping how vehicles are designed, manufactured and used, creating significant opportunities for companies across the mobility ecosystem.Electric vehicles (EVs) are moving rapidly into the mainstream as advances in battery technology extend driving ranges, charging infrastructure expands and ownership costs become more attractive. Elevated fuel prices, partly driven by geopolitical tensions in the Middle East, have further strengthened the economic appeal of EVs. The competitive landscape has also evolved dramatically. Tesla TSLA, once the clear leader in the EV market, now faces growing competition, especially from Chinese automakers.The industry's growth outlook remains compelling. According to the International Energy Agency, global EV sales climbed 20% year over year to more than 20 million units in 2025, representing about one in four new vehicles sold worldwide. Sales are projected to rise to 23 million units in 2026, accounting for nearly 28% of global new-vehicle sales. Europe is expected to be among the fastest-growing regions, with EVs approaching one-third of new car sales, while China is on track for electric vehicles to account for nearly 60% of total vehicle sales.Beyond electrification, autonomous driving is emerging as the next major growth engine. Rapid advances in artificial intelligence, sensors, cameras and connected-vehicle technology are making self-driving systems increasingly capable. According to Fortune Business Insights, the global autonomous vehicle market is projected to grow from $3.36 trillion in 2025 to $4.44 trillion in 2026 and reach $41.75 trillion by 2034, reflecting a CAGR of 32.3% between 2026 and 2034. Industry leaders such as Alphabet's GOOGL Waymo and Baidu are at the forefront of this technological shift.For investors, EVs and AVs represent a strong long-term opportunity. They combine growth, innovation and rising demand. Our Electric Vehicles & Autonomous Driving Screen highlights companies positioned to benefit from these trends, including NIO Inc. NIO, Mobileye Global Inc. MBLY, Hesai Group HSAI and Ouster OUST.Ready to uncover more transformative thematic investment ideas? Explore 39 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.4 Stocks to BuyNIO: It appears to be entering a stronger phase of its growth journey, supported by rising deliveries, an expanding product portfolio and improving operational execution. After years of heavy investment, the Chinese EV maker is beginning to see the benefits of its efforts as newer models gain traction and demand improves.A major catalyst is NIO’s broader vehicle lineup. The strong market reception of its flagship ES8 and ES9 models has helped drive delivery growth, while its Onvo and Firefly sub-brands are allowing the company to reach a wider range of customers across different price segments. This diversified approach could help NIO expand its addressable market and strengthen its competitive position.At the same time, NIO is making progress on profitability. Management’s focus on a more decentralized operating structure is helping improve cost control and capital allocation. These initiatives are translating into stronger vehicle margins.NIO’s battery-swapping ecosystem remains a key differentiator, with nearly 4,000 swap stations and a broad charging network enhancing customer convenience. Additionally, monetizing advanced driver assistance features through subscription services could unlock recurring, higher-margin revenue streams over time. With improving fundamentals and a Zacks Rank #2 (Buy), NIO is positioned to benefit from the continued expansion of the EV market.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Mobileye: As the automotive industry moves toward autonomous driving, Mobileye is well positioned to benefit from rising demand for advanced driver assistance systems (ADAS) and next-generation mobility solutions. The company’s broad technology portfolio, including Supervision, Chauffeur, Drive and its EyeQ platform, strengthens its position as automakers increasingly integrate smarter safety and autonomous features into vehicles.Mobileye’s core EyeQ business continues to benefit from higher camera-based ADAS adoption, customer wins and growing exports from Chinese automakers. The company is also expanding into higher-value solutions, with a new high-volume Cloud-Enhanced ADAS program from Stellantis expected to begin in 2027. This offering is expected to generate significantly higher gross profit per unit compared with base ADAS, while Surround ADAS could further support average selling price growth beginning in 2028.Beyond ADAS, Mobileye is advancing its autonomous mobility ambitions through strategic partnerships. Its collaboration with Volkswagen remains a key pillar, with MOIA beginning public rider testing in Hamburg and commercial deployments targeted in Orlando and Los Angeles over the next few years. The company is also developing a vertically integrated autonomous service platform for launch in at least one U.S. city in 2027.Supported by strong financial flexibility and solid fundamentals, Mobileye, which carries a Zacks Rank #2, is positioned to capitalize on the future of intelligent transportation.Hesai: As vehicles progress toward Level 3 autonomy, demand for high-performance sensing systems is expected to rise, creating significant growth opportunities for Hesai. Strong momentum in the ADAS market bodes well for the company. Hesai expects lidar shipments to nearly double to 3-3.5 million units in 2026, following record shipments of 1.6 million units in 2025.The transition toward multi-lidar vehicle architectures could further expand the opportunity for this Zacks Rank #2 company, as automakers deploy multiple sensors per vehicle to enhance safety and autonomous capabilities.At the 2026 Beijing Auto Show, Hesai’s lidar technology was featured across 56 vehicle models from 24 automotive brands, the highest among lidar suppliers. The company’s solutions are already used by leading automakers such as Audi, BYD, Xiaomi, Li Auto and Cadillac, while additional multi-lidar design wins with Li Auto, Xiaomi and Changan provide visibility into future growth.International expansion adds another growth avenue, with partnerships such as Mercedes-Benz for Level 3 autonomous vehicles in Europe and China, along with its entry into Japan through GAC Toyota. The launch of Picasso, the industry’s first 6D full-color lidar chip, and the upcoming ETX platform are expected to support broader adoption from 2027 onward. Hesai’s technology leadership positions it well to benefit from the long-term shift toward autonomous mobility.Ouster: It is positioning itself as a broader sensing and perception platform provider. While lidar remains central to its technology, the company has evolved beyond a traditional hardware business by combining lidar sensors with cameras, AI computing, perception software and proprietary AI models. This gives Ouster exposure to multiple high-growth markets, including autonomous vehicles, robotics, drones, smart infrastructure and humanoid robots.A key catalyst is the company’s REV8 platform, which strengthens its competitive position in next-generation sensing. Launched in 2026, REV8 is the industry’s first native color lidar platform, offering improved resolution, longer range, enhanced safety capabilities, greater scalability and lower production costs compared with previous generations. Its compliance with the Build America, Buy America (BABA) Act also creates opportunities in federally funded U.S. infrastructure projects.Early adoption trends are encouraging, with partnerships involving companies such as NVIDIA, FieldAI, Gecko Robotics, Fujifilm and ARGUS Interception highlighting demand across diverse applications. Ouster is also scaling production through an expanded manufacturing partnership with Benchmark Electronics, supporting annual capacity of more than 100,000 REV8 sensors under a long-term production agreement.With its broader Physical AI strategy, growing ecosystem of partners and expanding commercial opportunities, Ouster, carrying a Zacks Rank #2, is positioned to benefit from the increasing need for intelligent sensing solutions. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Elon Musk’s Super PAC Plans to Spend Up to $120 Million in Midterm Races Backing GOP Candidates Truthout

Ingersoll Rand Inc. IR reported second-quarter 2026 adjusted earnings of 86 cents per share, beating the Zacks Consensus Estimate of 83 cents by 3.6%. The bottom line increased 7.5% from the year-ago quarter.Revenues of $2.05 billion surpassed the consensus estimate of $1.96 billion by 4.5% and rose 8.5% year over year. Organic revenues increased 4.1%, while acquisitions and favorable foreign currency movements contributed 2.8% and 1.6%, respectively.IR's Orders and Organic GrowthIn the second quarter of 2026, its total orders increased 5.3% to $2.04 billion. Organic orders increased 1.6% year over year. Acquisitions added 2.4% to order growth, while foreign currency translation contributed 1.3%. Management noted healthy underlying demand and strengthening order momentum. Ingersoll Rand also reported double-digit order growth through the first four weeks of July, supported by the realization of longer-cycle orders that had been delayed during the first half and continued strength in short-to-medium-cycle demand.Segmental PerformanceIndustrial Technologies and Services generated revenues of $1.62 billion, up 8.7% year over year and accounting for about 79% of total revenues. Organic revenues increased 4.2%, with positive growth across all regions. Acquisitions and foreign currency added 2.8% and 1.7%, respectively. The segment recorded a book-to-bill ratio of 1.0, indicating that quarterly orders were broadly aligned with revenues.The segment's adjusted EBITDA increased 1.7% to $434.5 million, while its margin contracted 180 basis points to 26.8%. Organic orders were approximately flat as strong compressor activity, particularly in North America, was offset by the timing of longer-cycle blower and vacuum orders in Europe and continued pressure in the Middle East.Precision and Science Technologies recorded revenues of $426.7 million, up 7.7%. Organic revenues increased 3.9%, while acquisitions and currency contributed 2.9% and 0.9%, respectively. Organic orders rose 7.4%, led by low-double-digit growth in Life Sciences Technologies and mid-single-digit growth in Precision Technologies.The segment's adjusted EBITDA increased 15.2% to $134.5 million. Its adjusted EBITDA margin expanded 200 basis points to 31.5%, reflecting strong operational execution supported by the Ingersoll Rand Execution Excellence system.Ingersoll Rand Inc. Price, Consensus and EPS Surprise Ingersoll Rand Inc. price-consensus-eps-surprise-chart | Ingersoll Rand Inc. QuoteIngersoll Rand's Margin ProfileThe company’s total adjusted EBITDA increased 2.1% year over year to $519.9 million. However, the adjusted EBITDA margin contracted 160 basis points to 25.4%. The decline reflected challenges in offsetting inflation with pricing, primarily in China, continued commercial investments to support growth and higher corporate costs.In the quarter, IR’s cost of sales increased 11.6% to $1.19 billion, while selling and administrative expenses rose 8% to $400.8 million. Adjusted net income increased to $339.3 million from $325.2 million, though the adjusted net income margin declined to 16.6% from 17.2%.Ingersoll Rand's Cash Flow and LiquidityCash provided by operating activities totaled $295.9 million in the second quarter, up from $245.7 million in the year-ago quarter. Capital expenditures declined to $27 million from $35.3 million, lifting free cash flow to $268.9 million from $210.4 million. The free cash flow margin improved 200 basis points to 13.1%.IR ended the quarter with $3.8 billion in available liquidity, including $1.17 billion in cash and $2.6 billion of undrawn revolving credit capacity. The company paid out dividends of $8 million and repurchased shares worth $240 million. It also deployed $110 million toward acquisitions.Long-term debt (less of current maturities) was $4.07 billion, lower than $4.78 billion recorded at the end of 2025. Net debt to adjusted EBITDA remained at 1.7 times.IR's 2026 OutlookIngersoll Rand raised its 2026 revenue growth outlook to 4.5-6.5%. The forecast assumes organic growth of 1-3%, an approximately 1% currency benefit and a roughly 2.5% contribution from acquisitions.The company maintained its adjusted EBITDA guidance of $2.13-$2.19 billion and adjusted earnings forecast of $3.45-$3.57 per share. Management projects adjusted earnings to be near the high end of this range. Free cash flow conversion is projected at approximately 95% of adjusted net income.Ingersoll Rand's M&A PipelineThe company completed the acquisition of a U.S.-based blower manufacturer with approximately $50 million in annual revenues. The transaction expands Ingersoll Rand's blower technologies and aftermarket capabilities.IR also entered into a deal to acquire Fai Filtri, an Italian industrial filtration company with about $30 million in annual revenues, with closing expected in the fourth quarter. The acquisition pipeline includes more than 200 companies, with 11 additional transactions at the letter-of-intent phase.Zacks Rank and Stocks to ConsiderThe company currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the same space are discussed below:Applied Industrial Technologies AIT carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Applied Industrial’s earnings surpassed the consensus estimate in each of the trailing four quarters. The average earnings surprise was 4.0%. In the past 60 days, the Zacks Consensus Estimate for Applied Industrial’s fiscal 2026 bottom line has inched up 0.1%.RBC Bearings Incorporated RBC presently carries a Zacks Rank of 2. RBC Bearings’ earnings surpassed the consensus estimate in each of the trailing four quarters. The average earnings surprise was 6.2%. In the past 60 days, the Zacks Consensus Estimate for RBC’s fiscal 2027 earnings has increased 0.8%.Generac Holdings GNRC currently carries a Zacks Rank of 2. Generac Holdings’ earnings topped the consensus estimate twice and missed on the other two occasions in the trailing four quarters. The average earnings surprise was 7.4%. In the past 60 days, the Zacks Consensus Estimate for GNRC’s 2026 earnings has increased 0.4%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

New edit for clarification: I’m asking whether this specific kind of moral argument has its own recognized name, the same way utilitarianism, Kantian ethics, or virtue ethics each have their own name. The kind of argument I mean works like this: if you try to argue against the position, your own argument ends up relying on the very thing you were trying to deny, so denying it contradicts yourself.(ie. saying language doesn't exist) Gewirth’s theory is a somewhat known example of this kind of argument. Is there an established label for this style of reasoning, morality grounded in avoiding self-contradiction, the way there’s a label for ‘consequences matter most’ (utilitarianism) or ‘duty matters most’ (Kantian ethics)? Or does it just get discussed as Gewirth’s own personal theory without a broader category name? Gewirth’s Principle of Generic Consistency argues that any purposive(Goal-directed) agent is dialectically committed to affirming certain rights, on pain of self-contradiction. Is there a recognized meta-ethical category or school this kind of argument belongs to, beyond just ‘Gewirth’s own view’? I’m aware of Kant’s universalizability test as a related precedent, but I’m asking specifically about coherence or self-contradiction-based groundings for morality as a category, rather than about Kantian ethics broadly. Is this treated as its own recognized approach in the literature, or does it usually get folded into discussions of Kantian constructivism without its own separate classification?

Elon Musk’s AI Company Asks San José to Halt Lawsuit Over Deepfake Abuse KQED

Elora hotelier files defamation suits against residents over Facebook posts Penticton Herald

Cause of Big Bear bald eagle Jackie’s illness still unknown San Bernardino Sun

Top 20 University of Texas baseball players of all time Austin American-Statesman

Masco Corporation MAS delivered a mixed second quarter of 2026. Earnings and margins improved sharply, but sales moved lower.The quarter showed the benefit of pricing, cost savings, tariff refunds and share repurchases. It also showed that demand remains uneven, especially in North America and do-it-yourself paint.Masco’s Q2 Beat Came With a Sales MissAdjusted earnings per share rose 26% year over year to $1.64. That topped the Zacks Consensus Estimate by 26.2%.Masco Corporation Price and EPS Surprise Masco Corporation price-eps-surprise | Masco Corporation QuoteSales told a different story. Net sales declined 2.9% to $1.99 billion and missed the consensus mark by 4.6%, making the quarter difficult to judge on earnings alone.MAS Margin Gains Need Careful InterpretationAdjusted operating profit increased 17%, while adjusted operating margin expanded 410 basis points to 24.2%. Adjusted gross margin also improved to 43.8%.The margin gain needs context. Masco recognized a roughly $95 million net benefit from International Emergency Economic Powers Act tariff refunds, so investors should not treat the full improvement as structural. Pricing and cost initiatives helped, but the refund was a major driver.Masco’s Brands Support Its Core BusinessMasco’s portfolio remains anchored by Delta, Hansgrohe, Behr and other established brands across plumbing and architectural coatings. That brand base matters because much of the company’s demand is tied to repair and remodel activity rather than new construction.International plumbing sales rose 4% in local currency, while professional paint sales increased in the mid-single digits. New Delta, Brizo and Newport Brass collections, e-commerce gains and customer-service recognition support share retention during choppy demand.The Home Depot HD remains a relevant reference point for investors tracking repair-and-remodel spending. Sherwin-Williams SHW also offers a useful comparison for paint and coatings demand, particularly as Masco balances weakness in do-it-yourself paint with growth in the professional channel.MAS Still Faces Volume and DIY PressureNorth American sales fell 5% in local currency during the quarter. Lower volume partly offset the benefit from pricing and cost savings.Decorative Architectural Products also faced pressure. Do-it-yourself paint sales fell in the high-single-digit range, hurt by weak industry conditions and a customer transition in primers and applicators.Masco is still dealing with elevated commodity costs, employee-related inflation and tariff costs outside the refund benefit. Continued reliance on pricing could become harder if consumer demand stays soft.What MAS Signals Say About the Near TermThe bottom line is that Masco’s second-quarter earnings quality was mixed. Profitability improved, but the sales decline, volume pressure and temporary tariff-refund benefit limit how much investors should extrapolate from the margin expansion.MAS currently carries a Zacks Rank #3 (Hold). That rank points to a balanced near-term view rather than a clearly bullish or bearish signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The stock’s Style Scores are stronger. Masco has a VGM Score of A, including a Momentum Score of A and Value Score and Growth Score of B each. These scores indicate favorable style characteristics, but the Hold rank keeps the near-term stance measured as demand-related uncertainty persists. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Globus Medical GMED is scheduled to report second-quarter 2026 results on Aug. 6, after market closes.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.12 beat the Zacks Consensus Estimate by 21.74%. Globus Medical’s earnings topped estimates in each of the trailing four quarters, the average surprise being 26.26%.GMED’s Q2 EstimatesThe Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $786.9 million, suggesting 5.6% growth from the year-ago reported figure.The Zacks Consensus Estimate for second-quarter 2026 net earnings of $1.12 per share indicates a 30.3% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.Here’s a quick look at how the company is positioned leading up to this announcement.Factors Shaping GMED’s Q2 PerformanceWithin Musculoskeletal Solutions, Globus Medical is expected to have benefited from the continued strength of its U.S. Spine business. Categories such as standard fixation and MIS pedicle screws, expandable TLIF (Transforaminal Lumbar Interbody Fusion), ALIF (Anterior Lumbar Interbody Fusion), posterior cervical and cervical plating may have been key contributors to the performance. Meanwhile, power tools and products like DuraPro are likely to have helped the company continue capturing market share while creating incremental cross-selling opportunities.GMED likely continued to prioritize competitive recruiting within its Spine business during the second quarter, with efficient onboarding of sales representatives with required sets and inventories continuing to remain a key differentiator. Such efforts may have favorably supported the company's top-line performance in the second quarter of 2026.Globus Medical, Inc. Price and EPS Surprise Globus Medical, Inc. price-eps-surprise | Globus Medical, Inc. QuoteFurther, strong performance across the EMEA and Latin America regions likely supported International Spine business results. Its direct and distributor businesses in overseas markets are expected to have witnessed broad-based growth.The Trauma business is also expected to have made a very strong contribution in the second quarter. The ANTHEM Elbow plating system may have again emerged as a standout product, with demand exceeding expectations and prompting the company to deploy additional sets to support adoption. Growth in the Precice Limb Lengthening portfolio may have been driven by the company’s ability to fully meet market demand following the transition of manufacturing from the former NuVasive facilities to Globus Medical in early 2025.We also expect favorable revenue contribution from the Nevro acquisition. Since acquiring Nevro, Globus Medical has been focused on rightsizing the business to drive profitable sales growth while reducing excess spending to quickly adopt the Globus approach. Management highlighted meaningful profitability improvements in 2025 following a series of organizational and operational changes. The impact of those cost control measures was also evident in the first quarter of 2026 and hence likely continued to support second-quarter performance.Our model projects Musculoskeletal Solutions revenues to improve 6.1% year over year in the second quarter of 2026.Enabling Technologies is also expected to have delivered a solid performance in the second quarter of 2026. Amid increasing competition in the rapidly evolving robotics space, adoption of Globus Medical’s ExcelsiusGPS platform continues to be supported for its standard for ease and floor-mounted navigation-based robotic approach.Management highlighted that the deal pipeline remains strong, although the mix is moving toward leases and rentals rather than outright sales. While this shift reduces upfront revenue recognition compared with the historical sales model, it aligns with the strategy of refocusing the company’s capital approach to drive implant and other recurrent revenue product pull-through.Going by our model, Enabling Technologies revenues are projected to grow 6.5% year over year.Earnings Whispers for GMEDPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:Earnings ESP: Globus Medical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Key PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:CVS Health CVS has an Earnings ESP of +1.42% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 5.CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.79%. The Zacks Consensus Estimate for the company’s second-quarter EPS indicates an increase of 3.3% from the year-ago quarter’s figure.Cardinal Health CAH has an Earnings ESP of +1.24% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 16.4% from the year-ago quarter’s figure.Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is slated to release third-quarter fiscal 2026 results on Aug. 5.COR’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 1.59%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.3% from the year-ago quarter’s figure. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Short sellers have made a fortune betting against Elon Musk’s SpaceX — but the party won’t last forever New York Post

Technology licensing is evolving well beyond smartphones as connected devices, streaming platforms, artificial intelligence (AI) applications and next-generation wireless networks create new opportunities for intellectual property owners. Companies with broad patent portfolios are increasingly positioned to monetize innovation across multiple industries.InterDigital, Inc. IDCC is embracing this shift by expanding its licensing programs into cloud services, streaming, IoT and emerging communications technologies while continuing to invest in future standards development.How InterDigital Is Expanding Beyond MobileInterDigital has steadily diversified its licensing business beyond traditional handset royalties. While wireless patents remain its core asset, the company now licenses technologies used in streaming services, cloud platforms, consumer electronics, payment terminals, electric vehicle charging equipment and other IoT applications. Recent licensing activity reflects that broader strategy. The company reached a milestone agreement with Amazon covering devices and services, including Prime Video, while also signing IoT agreements with a leading fintech company for payment terminals and with KEBA for EV chargers. These relationships expand recurring licensing opportunities across markets that extend well beyond smartphones. InterDigital, Inc. Price and Consensus InterDigital, Inc. price-consensus-chart | InterDigital, Inc. QuoteCompanies such as QUALCOMM Incorporated QCOM and Dolby Laboratories, Inc. DLB likewise benefit from licensing advanced communications and media technologies, illustrating how intellectual property is becoming increasingly valuable across multiple technology ecosystems.Why IDCC Is Investing in AI and 6GInterDigital continues investing in technologies expected to shape future communications standards. Its research spans artificial intelligence, machine learning, advanced video technologies and 6G networking, all of which support the creation of new patent portfolios that can generate licensing revenue over time. The company also maintains a leadership role in global standards organizations, helping define future wireless specifications while positioning its intellectual property for broad industry adoption. Continued innovation in AI-native networking and advanced video technologies supports licensing opportunities across consumer electronics, industrial applications and connected infrastructure. How InterDigital Strengthens Licensing PowerBeyond research, InterDigital continues to reinforce its negotiating position through both commercial agreements and intellectual property enforcement. The Amazon agreement resolved pending litigation while establishing a framework for determining final licensing terms through binding arbitration. The company also secured two injunctions against Disney from Europe's Unified Patent Court covering video encoding patents across 11 European countries. Combined with new licensing agreements in the IoT market, these developments reinforce the strength of InterDigital's patent portfolio and may improve its position in future licensing negotiations. What Industry Trends Could Challenge IDCCDespite favorable long-term trends, several factors could limit growth. Technology evolves rapidly, requiring continuous investment in research to maintain competitive patent portfolios and relevance within changing wireless standards.The company also faces ongoing intellectual property enforcement costs, while licensing revenue can fluctuate based on agreement timing and arbitration outcomes. In addition, macroeconomic pressures and weaker demand in portions of the consumer electronics and IoT markets could reduce licensing activity or delay customer investments. Customer concentration remains another important consideration for investors evaluating long-term performance. Why IDCC's Ratings Matter for Trend InvestorsInterDigital's strategy aligns with several of the technology industry's fastest-growing themes, including AI, cloud computing, streaming services and connected devices. As these markets expand, the company's diversified licensing model provides additional avenues for recurring royalty growth.The stock currently sports a Zacks Rank #1 (Strong Buy), reflecting favorable earnings estimate momentum. You can see the complete list of today’s Zacks #1 Rank stocks here. However, investors should also consider its Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. While the Zacks Rank points to a favorable near-term earnings outlook, the Style Scores indicate that valuation, growth characteristics and recent price momentum remain mixed, providing additional context when evaluating the company's longer-term technology opportunity. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

LKQ Corporation LKQ reported second-quarter 2026 adjusted earnings of 67 cents per share, missing the Zacks Consensus Estimate of 73 cents by 8.2%. The bottom line declined 20.2% from 87 cents reported in the year-ago quarter.Quarterly revenues fell 3% year over year to $3.41 billion and missed the consensus mark of $3.50 billion by 2.7%. Europe’s ERP implementation challenges overshadowed positive organic growth in North America and Specialty.LKQ Corporation Price, Consensus and EPS Surprise LKQ Corporation price-consensus-eps-surprise-chart | LKQ Corporation QuoteLKQ Sees North America Return to GrowthNorth America generated revenues of $1.47 billion, up from $1.44 billion in the prior-year quarter. Parts and services organic revenues increased 0.5%, marking the segment’s first quarterly organic growth since 2023.Pricing actions to recover tariff costs and offset inflation supported sales, while repairable claims declined between 1% and 3%. Other revenues advanced 20.5% on higher metals prices and increased volumes. Alternative-parts utilization exceeded 40%, reaching a record level.North America’s gross profit increased to $622 million from $619 million. However, gross margin contracted 40 basis points to 42.5% due to the dilutive impact of tariff-related pricing, lower vendor rebates and an unfavorable customer mix.North America’s quarterly segment EBITDA declined to $207 million from $224 million a year earlier. The segment EBITDA margin contracted to 14.1% from 15.5%, partly reflecting a $10 million legal reserve that reduced the margin by roughly 70 basis points.LKQ Corp Faces Europe ERP SetbackEurope’s revenues declined to $1.46 billion from $1.61 billion a year earlier. Organic parts and services revenues fell 12.6%, partly offset by a 2.1% foreign-exchange benefit and a 0.9% contribution from acquisitions and divestitures.The rollout of a common ERP platform in Germany disrupted service and reduced quarterly revenues by an estimated $140 million. Soft demand and weaker commercial execution in the United Kingdom and Benelux added to the pressure.Segment EBITDA fell to $109 million from $151 million, while the EBITDA margin contracted to 7.5% from 9.4%. The company estimated that the German ERP disruption lowered EBITDA by roughly $50 million, while volume pressure in the United Kingdom and Benelux reduced it by about $30 million.LKQ Specialty Sales Rise but Costs WeighSpecialty revenues increased to $488 million from $465 million in the second quarter of 2025. Organic growth was 4.5%, supported by higher volumes across marine, recreational vehicle and automotive product lines.Gross profit rose to $125 million from $118 million, with the margin improving 20 basis points to 25.6%. Tariff refunds and increased volumes more than offset an unfavorable sales mix.Despite the top-line growth, segment EBITDA declined to $33 million from $39 million. The EBITDA margin fell to 6.7% from 8.5%, reflecting an $8 million increase in credit losses and higher transportation-related expenses.LKQ Corp Margins Contract as SG&A ClimbsConsolidated gross profit decreased 2.6% to $1.32 billion. Gross margin edged up to 38.8% from 38.6% as improved pricing and product mix in Europe helped offset weaker sales volumes.Selling, general and administrative expenses rose 3.3% to $990 million and increased to 29% of revenues from 27.3%. North America’s costs included a $10 million legal reserve, while Europe incurred higher transportation expenses and unfavorable currency effects.Operating income dropped 24.7% to $225 million, with the operating margin shrinking to 6.6% from 8.5%. Adjusted segment EBITDA declined 15.6% to $349 million, and the related margin contracted 160 basis points to 10.2%.LKQ Cash Flow Improves in the QuarterLKQ generated operating cash flow of $111 million and free cash flow of $60 million during the second quarter. For the first six months of 2026, operating cash flow totaled $55 million, while free cash flow was negative $36 million.As of June 30, 2026, the company had $301 million in cash, down from $319 million as of Dec. 31, 2025. It had $4 billion in total debt and available liquidity of $1.93 billion. Its total leverage ratio was 2.8 times EBITDA.LKQ returned $129 million to shareholders during the quarter, including $52 million used to repurchase 1.9 million shares and $77 million in dividends. On July 28, 2026, the company also declared a quarterly dividend of 30 cents per share.LKQ Corp Cuts 2026 OutlookThe company now expects 2026 organic parts and services revenues to decline between 1% and 3% compared with the previous estimated range of a 0.5% decline to 1.5% growth.Adjusted earnings per share are projected between $2.60 and $2.90, down from the prior forecast of $2.90-$3.20. Operating cash flow guidance is projected to be in the range of $825 million to $1.03 billion, down from the earlier estimate of $900 million to $1.10 billion.Free cash flow is now expected between $625 million and $775 million compared with the previously expected range of $700-$850 million. The revised outlook assumes a more gradual recovery in Germany and continued softness in the United Kingdom and Benelux. The company’s strategic review remains active, with LKQ continuing discussions with multiple parties.LKQ currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Key Releases From Auto SpaceGeneral Motors Company GM reported second-quarter 2026 adjusted earnings of $3.57 per share, up 41.3% year over year. The figure beat the Zacks Consensus Estimate of $3.13 by 14.06%. Revenues increased 1.9% to $48.03 billion and surpassed the consensus estimate of $46.56 billion by 3.15%. Strong pricing, lower costs and disciplined incentives supported results. General Motors raised its full-year adjusted EBIT guidance to $14-$16 billion from $13.5-$15.5 billion. Adjusted earnings are now projected at $12-$14 per share, up from the prior range of $11.50-$13.50.Tesla, Inc. TSLA reported second-quarter 2026 adjusted earnings of 33 cents per share, which declined 17.5% year over year. The figure missed the Zacks Consensus Estimate of 50 cents by 34%. Revenues advanced 25.5% to $28.24 billion and surpassed the consensus estimate of $25.81 billion by 9.41%. Tesla expects 2026 capital expenditures to exceed $25 billion and rise further over the next two to three years. Genuine Parts Company GPC reported second-quarter 2026 adjusted earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.10 by 2.38%. The bottom line increased 2.4% from $2.10 in the year-ago quarter. Revenues rose 6% year over year to $6.54 billion and surpassed the consensus estimate of $6.39 billion by 2.36%. Genuine Parts reaffirmed its 2026 adjusted earnings guidance of $7.50-$8 per share and total sales growth outlook of 3-5.5%. Genuine Parts ended June with $2.3 billion of liquidity, including $559 million in cash. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

We expect Amgen AMGN to beat expectations when it reports second-quarter 2026 results on Aug. 4 after market close. In the last reported quarter, the company's earnings beat expectations by 8.88%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $9.45 billion and $5.60 per share, respectively.Factors to Consider for AmgenIn the second quarter, Amgen’s product sales are expected to have been driven by strong volume growth of products like Repatha, Tezspire, Uplizna and Evenity, among others. However, price declines for some products and increases in 340B program utilization are likely to have offset some of the gains from volume increases.The Zacks Consensus Estimate for Repatha, Tezspire, Uplizna and Evenity sales is pegged at $907.0 million, $483.0 million, $306 million and $636.0 million, respectively.Sales of key drugs, Prolia and Xgeva, are likely to have declined as they have lost patent exclusivity.Patents for Prolia and Xgeva expired in February 2025 in the United States, while the same expired in some European countries in November 2025. The erosion in their sales was in line with expectations in the first quarter. Accelerated sales erosion is expected over the remainder of 2026 as several biosimilars have been launched globally. The Zacks Consensus Estimate for Prolia and Xgeva is pegged at $728.0 million and $356.0 million, respectively.Sales of some other drugs like Kyprolis, Vectibix, Nplate and Lumakras/Lumykras are likely to have risen in the quarter. Sales of new cancer drug Imdelltra (tarlatamab) are likely to have risen sequentially, driven by volume growth. The drug was approved by the name of Imdylltra in the EU in June.In Amgen’s inflammation portfolio, Enbrel sales are likely to have declined due to declining prices. Otezla sales are likely to have been hurt by lower pricing in the United States and generic erosion in the EU.The Zacks Consensus Estimate for Otezla is $562.0 million, while that for Enbrel is $466.0 million.Amgen’s new biosimilar products like a biosimilar version of J&J’s Stelara called Wezlana and Regeneron’s REGN Eylea called Pavblu are also likely to have contributed to sales growth like the past few quarters. Wezlana’s sales are expected mostly from ex-U.S. markets while Pavblu’s sales are expected to have risen sequentially, driven by volume growth.Lower revenues from oncology biosimilars (Kanjinti and Mvasi) due to increased competitive pressure are expected to have hurt the top line. Sales of legacy established products are also expected to have declined.In the second quarter, adjusted operating margin is expected to be in line with the first-quarter operating margin of 45.3%.Investors will look for updates on Amgen’s important pipeline candidate, MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity, on the second-quarter conference call.AMGN’s Earnings Surprise HistoryThis large biotech’s performance has been strong, with earnings beating estimates in the trailing four quarters. The company delivered a four-quarter earnings surprise of 11.82%, on average.Amgen’s stock has risen 18.4% so far this year compared with an increase of 2.8% for the industry.Image Source: Zacks Investment ResearchWhat Our Model Says for AMGNOur proven model predicts an earnings beat for Amgen this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.Earnings ESP: Amgen’s Earnings ESP is +0.70%. The Zacks Consensus Estimate is pegged at $5.60 per share, while the Most Accurate Estimate is pegged higher at $5.64 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Amgen has a Zacks Rank #3.Other Stocks to ConsiderHere are two drug/biotech stocks that also have the right combination of elements to beat on earnings this time around:Jazz Pharmaceuticals JAZZ has an Earnings ESP of +0.41% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Jazz stock has risen 52% so far this year. JAZZ beat estimates in three of the last four quarters while missing in one. The company has a four-quarter earnings surprise of 10.73%, on average. Jazz is scheduled to report second-quarter results on Aug. 3.Pfizer PFE has an Earnings ESP of +2.07% and a Zacks Rank #3 at present.Shares of Pfizer have risen 0.1% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 21.93%. Pfizer is scheduled to report second-quarter results on Aug. 4. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

New fossil discoveries from China are being hailed as evidence that could reshape our understanding of the origin of complex animal life. Does the new find solve the mystery of the Cambrian explosion? Are the headlines about these fossils justified? Are these in fact the long-lost ancestors of the Cambrian animals we’ve been looking for? On this ID The Future, host Andrew McDiarmid welcomes Dr. Casey Luskin to the show to to examine the evidence, ambiguity, and ongoing controversy surrounding newly reported Ediacaran bilaterian fossils. Source